Abstract 323P
Background
Ovarian cancer is a general phrase that may be applied to any malignancy that affects the ovaries and is one of the worst malignancies. Aside from the number of its population, the Asian population also has a very diverse culture and socioeconomic development. Pretreatment peripheral blood cell counts, including lymphocytes, monocytes, and neutrophils, are major prognostic indicators in various cancers. This study aimed to evaluate the role of NLR, PLR, and LMR as prognostic biomarkers in ovarian cancer among the Asian population in a meta-analysis design.
Methods
This study assessed the association between NLR, PLR, and LMR and ovarian cancer as prognostic biomarkers based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) protocol. The literature research was performed by systematically searching PubMed, ScienceDirect, and Google Scholar using the search terms based on BOOLEAN operators. Revman software ver 5.4.1 was employed for all statistical analyses, and p-values<0.05 were considered statistically significant.
Results
This study included 17 studies conducted in various Asian countries according to inclusion and exclusion criteria. Significant results were found in both univariate and multivariate analysis for NLR, PLR, and LMR to overall survival [(Univariate) NLR: HR 2.04; 95% CI 1.61 – 2.58; p<0.001, PLR: HR 2.04; 95% CI 1.26 – 3.30; p<0.001, LMR: HR 0.53; 95% CI 0.40 – 0.72; p<0.001. (Multivariate) NLR: HR 1.65; 95% CI 1.22 – 2.22; p<0.001, PLR: HR 2.12; 95% CI 1.70 – 2.66; p<0.001, LMR: HR 0.54; 95% CI 0.37 – 0.80; p=0.002]. Significant results were also found in both univariate and multivariate analysis for NLR and PLR to disease-free survival [(Univariate) NLR: HR 2.19; 95% CI 1.36 – 3.54; p<0.001, PLR: HR 1.95; 95% CI 1.31 – 2.91; p<0.001. (Multivariate) NLR: HR 1.37; 95% CI 1.21 – 1.56; p<0.001, PLR: HR 1.78; 95% CI 1.45 – 2.17; p<0.001.
Conclusions
NLR, PLR, and LMR can be considered as prognostic biomarkers in ovarian cancer. Further studies are needed to re-evaluate these findings in the Asian population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
I.G.P. Supadmanaba.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract
570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Presenter: Wenxiang Ji
Session: Poster Display
Resources:
Abstract